Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT07120698 2026-01-05

CTONG 2508

Phase 2 Recruiting

115 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06512207 2025-09-09

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Phase NA Recruiting

80 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05116462 2025-06-26

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

506 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03812549 2025-03-04

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Phase 1 Completed

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT05549037 2025-02-19

PACIFIC15

Phase 3 Recruiting

210 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05979818 2024-11-19

BRIO

Phase 1 Recruiting

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06620822 2024-10-01

Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial

296 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04167657 2024-09-19

STAR

Phase 2 Completed

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06604351 2024-09-19

Example

39 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05244213 2024-07-08

NEOTIDE

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06267144 2024-02-20

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06221462 2024-01-25

PRIORITY

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05088967 2024-01-16

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Phase 1 Terminated

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06198907 2024-01-10

JACKPOT33

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04728724 2023-09-13

Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer

Phase 2 Recruiting

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03150875 2023-02-28

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Phase 3 Completed

290 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Phase 1 Completed

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Phase 1 Completed

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04459611 2022-07-12

neoSCORE

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04612673 2020-11-03

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04371796 2020-05-01

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04106180 2019-09-26

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

63 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03874000 2019-03-19

SMART

43 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative